Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis

Chao Gao1,*, Cuiting Peng1,2,*, Yaojie Shi1, Xinyu You1,2, Kai Ran1, Lu Xiong1, Ting-hong Ye1, Lidan Zhang1, Ningyu Wang1, Yongxia Zhu1, Kun Liu1, Weiqiong Zuo1, Luoting Yu1 & Yuquan Wei1

New chemotherapeutic compounds are needed to combat multidrug-resistant *Mycobacterium tuberculosis* (*Mtb*), which remains a serious public-health challenge. Decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1 enzyme) has been characterized as an attractive therapeutic target to address this urgent demand. Herein, we have identified a new class of DprE1 inhibitors benzothiazinethiones as antitubercular agents. Benzothiazinethione analogue SKLB-TB1001 exhibited excellent activity against *Mtb* in the Microplate Alamar blue assay and intracellular model, meanwhile SKLB-TB1001 was also highly potent against multi-drug resistant extensively and drug resistant clinical isolates. Importantly, no antagonism interaction was found with any two-drug combinations tested in the present study and the combination of SKLB-TB1001 with rifampicin (RMP) was proved to be synergistic. Furthermore, benzothiazinethione showed superb in vivo antitubercular efficacy in an acute *Mtb* infection mouse model, significantly better than that of BTZ043. These data combined with the bioavailability and safety profiles of benzothiazinethione indicates SKLB-TB1001 is a promising preclinical candidate for the treatment of drug-resistant tuberculosis.

Tuberculosis (TB) continues to be a major health threat affecting the world today. According to the World Health Organization (WHO) report1, there were 9.6 million active TB cases and 1.5 million TB-induced deaths in 2014. The current drug therapy regimen for TB was proposed 40 years ago2. However, long duration of therapy, severe side-effects and issues of non-compliance have hindered this regimen and the appearance of drug resistance has worsened this situation3–5.

In response to the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) strains of *Mycobacterium tuberculosis* (*Mtb*), numerous initiatives and efforts are being undertaken to combat this global killer. There appears some new therapeutic anti-tuberculosis agents especially in the past 5–6 years after several decades of near inactivity to fill the drug pipeline6–10. And recently, Sirturo (bedaquiline, also known as TMC207) and delamanid (OPC67683) were approved as part of combination treatment for MDR tuberculosis11–13. While there will be a time for vastly expanded access to these new agents due to some safety risks, and the search for effective clinical candidates is vital in order to sustain the tuberculosis drug pipeline14–16.

Decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1) have been characterized as one of the most attractive targets for anti-tuberculosis drug discovery17–19. As the components of decaprenylphosphoryl-β-D-ribose 2′-epimerase complex, DprE1 and DprE2 catalyze the epimerization of decaprenylphosphoryl-β-D-ribose (DPR) to decaprenylphosphoryl-β-D-arabinofuranose (DPA) which is an important precursor for the synthesis of mycobacterial cell wall arabinans20. Some new chemical entities (NCE) are proven to be potent against MDR/XDR-TB as covalent or non-covalent inhibitors of the DprE1 enzyme21–26. *Nitro*-benzothiazinones (BTZs) are known the...
most advanced scaffold among these NCEs. And BTZ043, which acts by forming a covalent bond with Cys387 in the active site pocket of DprE1, is nearing phase I clinical trials with a MIC of 1 ng/mL\(^2\). More recently, the pre-clinical candidate arose from lead optimizations, PBTZ169, has shown great promise for the treatment of tuberculosis and is poised to enter clinical trials\(^2\). The SAR studies and the detailed mechanistic studies indicate that the NO\(_2\) group at position 8 and the sulfur atom at position 6 also play an important role in maintaining anti-tubercular activity\(^2\,2\,3\,4\). In one of our endeavors to find a new antitubercular agent, we discovered a new series of benzothiazinones with satisfactory antimycobacterial properties\(^6\,7\). Inspired by the promising results from BTZ043, PBTZ169 and the antitubercular potential of the sulfur rich heterocycles in our earlier studies, we herein explored the antitubercular potential of a new sulfureous scaffold benzothiazinethione.

Results

Identification of benzothiazinethiones. Benzothiazinethiones were obtained from the relevant benzothiazinones (BTZs), and the general synthetic route of BTZs can be found in previous studies\(^6\,7\). We investigated a series of compounds with representative properties and used the microplate alamar blue assay to screen for activity against \(M.\) \(tuberculosis\) (Supplementary Table S1). One compound in particular, 8-nitro-2-(1,4-dioxaoctahydro-8-azaspiro[4.5]decan-8-yl)-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazine-4-thione (SKLB-TB1001) (Fig. 1), was found to be equipotent to BTZ043 and PBTZ169 against replicating H37Rv (Table 1) and more potent than isoniazid (INH). These compounds were evaluated for cytotoxicity for Vero, A549 and J774A.1 cells. SKLB-1001 had relatively high 50% inhibitory concentrations (IC\(_{50}\))s, indicating relatively good selectivity. When considering such factors as manufacturing, physicochemical and pharmacokinetic properties along with the antimicrobial activity \(in\) \(vitro\) (Supplementary Tables S1 and S2), SKLB-TB1001 was selected for further study.

The anti-tubercular activity was also tested on 5 clinically isolated strains (Table 2). Notably, SKLB-TB1001 was similarly active against MDR clinical isolates of \(M.\) \(tb\) showing resistance to isoniazid and rifampicin in addition to streptomycin and also equivalently potent for XDR strains which were resistant to all tested drugs. The results of our evaluation indicated that SKLB-TB1001 exhibits satisfactory anti-mycobacterial activity on both drug-susceptible and drug-resistant strains, suggesting it has no cross-resistance with any of the currently used anti-TB drugs and its potential for use against drug-resistant \(Mtb\) strains.

As shown in Table 1, \(M.\) \(avium\) was resistant to SKLB-TB1001 and BTZ043, consistent with previous studies on DprE1 inhibitors. The computational docking and differential scanning calorimetry (DSC) of DprE1 with SKLB-TB1001 also indicated the inhibition of DprE1 by SKLB-TB1001 (Supplementary Figs S1 and S2).

In addition, SKLB-TB1001 inhibits growth of intracellular \(Mtb\) (Fig. 2). The bactericidal activity against \(M.\) \(tuberculosis\) Erdman in J774A.1 macrophages was observed for SKLB-TB1001 as well as for BTZ043 and rifampin controls. SKLB-1001 and BTZ043 effected a 2.1 and 2.2 log reduction in viability at 0.02 \(\mu\)g/mL, respectively, while rifampin demonstrated more modest activity (Supplementary Table S3).

Interaction of SKLB-TB1001 with rifampin, isoniazid, moxifloxacin and linezolid. The interaction of SKLB-1001 with chemically diverse antitubercular agents was examined \(in\) \(vitro\) using checkerboard synergy assay (Table 3). The interaction between two agents in combination can be described as synergistic, additive and antagonistic. Table 3 lists the MIC of each individual drug, as well as fractional inhibitory concentration

![Figure 1. The structure of compound SKLB-TB1001.](image-url)
Table 2. Activity of benzothiazinethione against drug-resistant TB clinical isolates. SM, streptomycin; EMB, ethambutol; KM, kanamycin; INH, isoniazid; RMP, rifampicin; LVFX, levo-ofloxacin; OFLX, ofloxacin; MOX, moxifloxacin; CPM, capreomycin; AMK, amikacin. M3, 4, 8 and 15 are clinical isolated multidrug-resistant strains. X18 and 75 are clinical isolated extensively drug-resistant strains. N.D. indicates not determined.

Figure 2. Antimicrobial activity of SKLB-TB1001 against M. tuberculosis Erdman in J774A.1 cells. Triplicate cultures were treated with antitubercular agents at 0.02 μg/mL. Values represented mean ± SD. D0 and D7 represent the CFU counts of untreated control at the beginning and end of incubation, respectively. P values for comparison of two groups were determined by 2-tailed Student’s t test (*P < 0.05; **P < 0.01; ***P < 0.001 vs D7 group; NS means having no statistically significant).

Table 3. Interactions of SKLB-TB1001 and existing TB drugs against M. tuberculosis H37Rv in vitro. LZD, Linezolid; FICI, Fractional inhibitory concentrations index. MABA checkerboard assays were used to characterize interaction of benzothiazinethione with existing TB drugs.
index (FICI) of SKLB1001 in combination with front-line and experimental anti-TB agents. The data indicate that the combination of SKLB-TB1001 and RMP was synergistic (FICI = 0.22): MIC of SKLB-TB1001 in the presence of RMP was decreased 5-fold, and the MIC of RMF in the presence of SKLB-TB1001 was decreased 6-fold. Nevertheless, FICI of BTZ043 in combination with RMP was 0.85 suggesting an additive interaction. The MIC of SKLB-1001 in the presence of isoniazid or moxifloxacin was clearly lower than the MIC when it was used alone (FICI = 0.68, 0.97, respectively). The combination of SKLB-TB1001 and linezolid caused a FICI of 1.34 indicating that the drugs act additively against M.tb. No antagonism interaction was found with any two-drug combination tested in the present study.

Pharmacokinetics of SKLB-TB1001. Pharmacokinetic properties of benzothiazinethione analogue SKLB-TB1001 and benzothiazineone analogue BTZ043 were investigated in SD rats (Table 4, Fig. 3). Oral administration of SKLB-TB1001 and BTZ043 at 5 mg/kg resulted in rapid absorption (T\textsubscript{max} 1.13 and 0.25 hours) and moderate elimination half-life (t\textsubscript{1/2} 1.45 and 1.22 hours). The comparison of peroral AUC with intravenous AUC of SKLB-TB1001 in plasma over time resulted in an apparent oral bioavailability of 44.4%, which was significantly higher than that of BTZ043 (F 29.5%). These results indicated that benzothiazinethione analogue SKLB-TB1001 have adequate PK properties enabled in vivo efficacy.

Efficacy of SKLB-TB1001 in the acute Mtb Erdman infection mouse model. Table 5 and Fig. 4 showed the activity of antitubercular drugs on mice infected with M.tb Erdman. Oral RMP at 15 mg/kg was positive control. RMP reduced bacterial concentration in lungs 2.5 logs, compared to bacterial concentration in tissues of vehicle control group. Encouragingly, SKLB-TB1001 treatment of infected mice at 150 mg/kg daily for 4 weeks resulted in a reduction of M.tb CFU in lungs by 3.4 logs compared to the vehicle group and 0.87 logs reduction compared to treatment initiation, which was clearly more effective than RMP at 15 mg/kg(P < 0.001). In mice treated with 150 mg/kg of SKLB-TB1001, the M.tb burden was reduced by the

| Comp. | C\textsubscript{max} (ng/ml) | T\textsubscript{max} (h) | T\textsubscript{1/2} (h) | AUC (ng * h/mL) | F (%) |
|-------|-----------------|-----------------|-----------------|-----------------|-----|
| TB1001 | 193             | 1.13            | 1.45            | 847             | 44.4|
| BTZ043 | 543             | 0.25            | 1.22            | 899             | 29.5|

Table 4. Oral pharmacokinetic parameters of compounds in SD rats. C\textsubscript{max}, maximum plasma concentration; T\textsubscript{max}, time of peak plasma concentration; T\textsubscript{1/2}, terminal half-life for elimination; AUC, area under the curve (t = 0 to infinity); F, absolute oral bioavailability. F = AUC (p.o., 5 mg/kg)/AUC(i.v., 5 mg/kg).

| Day    | Log\textsubscript{10} CFU (SD) | Unreated | Vehicle | RMP | TB1001 | BTZ043 |
|--------|-------------------------------|---------|---------|-----|--------|--------|
| Day-3  | 2.90 (2.40)                   | N.D.    | N.D.    | N.D. | N.D.   | N.D.   |
| Day-10 | 3.72 (3.25)                   | N.D.    | N.D.    | N.D. | N.D.   | N.D.   |
| Day-36 | N.D.                          | 6.27 (5.85) | 3.73 (3.19) | 2.84 (2.93) | 6.31 (5.85) |

Table 5. Bacterial burden in mouse lungs. Log\textsubscript{10} colony forming unit (CFU) counts in lungs was determined by calculating the bacteria loads in organs from the untreated group and treated groups. Mean log\textsubscript{10} CFU per lung (SD) are presented. N.D. indicates not determined.
Acute toxicity study. The maximum non-toxic dose of SKLB-TB1001 in vivo is greater than 1 g/kg in BALB/c mice. There was no death in acute single dose toxicity studies in BALB/c mice. All the mice behaved normally when administering by celiac injection. No significant changes in general appearance or behavioral pattern were noted till the end of 14 days. No statistically significant differences in body weight, viscera, biochemical parameters and Hematology index between treatment group and control group (Table 6, Supplementary Fig. S3). No observable pathological changes were found in heart, liver, lung, kidneys and spleen (Supplementary Fig. S4).

Discussion

New agents and therapeutic methods for TB, especially MDR- and XDR-TB, are greatly needed in the global effort to control this deadly disease33. DprE1 enzyme and Benzothiazinone analogues have displayed some promising results for tuberculosis treatments. We described herein a new scaffold, benzothiazinethione, which was obtained from the thionation of benzothiazinone and provided new insight into the structural and pharmacological requirements for DprE1 inhibitors as potent antitubercular agents. Generally, benzothiazinethiones maintained the antitubercular activity at different levels. In the series of studies described here, SKLB-TB1001, which was equivalent to BTZ043, exhibited potent activity against either M. tuberculosis standard strain or drug-resistant strains in vitro. Despite its low aqueous solubility, SKLB-TB1001 exhibited favorable PK properties after oral administration. In the acute infection mouse model, after 4 weeks of drug treatment, the efficacy of SKLB-TB1001 was more obvious than that for rifampicin and was better than that for BTZ043. In the in vitro combination study, no antagonism occurred and synergistic or enhanced interactions predominated. These results demonstrated that SKLB-TB1001 is a potential preclinical candidate.
Since multi-drug therapy is essential to cure TB infections, we explored the interactions between SKLB-TB1001 with the frontline TB drugs and new anti-TB drug candidates in clinical trials. No antagonism was observed between SKLB-1001 and the tested compounds, and the additive interaction was observed when SKLB-TB1001 combination with isoniazid, moxifloxacin or linezolid. Interestingly, SKLB-TB1001 showed synergy with rifampicin, while this synergistic interaction did not occur between rifampin and BTZ043 or PBTZ169 in this study and the previous reports. A definitive explanation for the synergy interaction between SKLB-TB1001 and rifampicin against Mtb H37Rv is not yet available. The synergistic action in a drug collaboration depends on the drug targets and the mode of actions of the individual compounds. Perhaps the synergy was due to weak interactions by DprE1 inhibition leading to better penetration of RMP. However, the previous DprE1 inhibitors, BTZ043 and PBTZ169, did not show any synergistic interaction when used in combination with RMP in the previous studies, suggesting that the effect on the cell wall structure of Mtb by SKLB-TB1001 does not necessarily contribute to the synergistic interaction in RMP + SKLB-1001 combination.

Hypothetically, the introduction of S atom in the BTZ structure could cause some unknown mechanism triggered by SKLB-TB1001. On the basis of the structure of benzothiazinethione and benzothiazine, SKLB-1001 may generate some sulfur-containing metabolites or as an organic SO2 donor. Recently, sulfur dioxide has been shown to have antimycobacterial activity and the Mtb inhibitory activity in part depended on its ability to induce stress by affecting cellular redox equilibrium and causing damage to DNA. In addition, these sulfur-containing metabolites may bond to DNA or RNA due to the nucleophilicity of S atom. While, these transformations occur in bacterial only or these intermediates are well tolerated in normal cells according to the high IC50s of SKLB-1001 for Vero and J774A.1 cells. Since rifampicin is a RNA polymerase inhibitor, the damages to biomacromolecules caused by SKLB-1001 could exert a noticeable effect on activity of RMP. Notably, two anti-TB drugs moxifloxacin and linezolid, which act on the same targets of Mtb, did not show synergistic interaction when used in combination with SKLB-TB1001. It indicated that benzothiazinethione enhance the activity of other antibiotics selectively. Future work will include identifying the metabolites of SKLB-1001 and possible targets to fully reveal the mechanisms of benzothiazinethiones. With the in vitro positive (synergistic activity) drug interactions, we have initiated a series of studies with murine models of TB to confirm whether synergy also occurs in vivo.

In addition to its promising in vitro bactericidal activity, the benzothiazinethione analogue SKLB-TB1001 significantly reduced the lung CFU counts of mice after 4 weeks of treatment. Interestingly, there was no significant change in CFU counts of mice receiving BTZ043 treatment compared with control in this model. The performance of BTZ043 in the Mtb Erdman infection mouse model was apparently different with the previous studies which conducted in the H37Rv infection model. In the in vitro studies, SKLB-TB1001 and BTZ043 exhibited similar antimicrobial activity including in the tuberculosis Erdman infection macrophase model. Since there was a general correlation between activities in the in vitro and mouse models, we speculated that the invalidation of BTZ043 was due to some unknown changes of pharmacological properties in vivo. Besides, the unique mechanism of SKLB-TB1001 may benefit enhancing its efficacy in the mouse model. In order to exclude the influence caused by M. tuberculosis strains used for in vivo infections, we are retesting the efficacy of SKLB-TB1001 against a second M. tuberculosis strain in mouse models. Meanwhile, work focusing on the possible mechanisms of discrepancies between BTZ043 performed in different models and the pharmacological properties of SKLB-TB1001 are in progress.

Some appreciable limitations, such as the issues of pharmacokinetics, bioavailability, safety and in vivo availability could result in development failures. In this case, the oral bioavailability for SKLB-TB1001 in a lipophilic formulation was favorable (44.4%) and significantly higher than that of BTZ043 (29.5%), which suggested its great potential in clinical trials at higher doses. With demonstrated in vitro activity, SKLB-TB1001 also showed superb in vivo antitubercular efficacy by reducing bacterial load of 3.4 log units in lungs over a period of 4 weeks’ treatment, superior over that of RMP (15 mg/kg). In addition, in vitro and in vivo safety assessment of SKLB-TB1001 in mouse revealed a reliable security of SKLB-TB1001. Importantly, the new chemotype, benzothiazinethione, seems able to overcoming these major hurdles in preclinical drug development to some extent. When compared with benzothiazine, it is likely that SKLB-TB1001 reflects the differences on pharmacokinetic and pharmacology properties. With these unique features of the benzothiazinethione analogue SKLB-TB1001 could be a valuable preclinical candidate.

Methods

Materials. The following mycobacterial strains used in assays in vitro were maintained in Shanghai pulmonary hospital: Mycobacterium avium; drug-resistant clinical isolates. Mycobacterium tuberculosis Erdman and Mycobacterium H37Rv were maintained in University of Illinois at Chicago.

Benzothiazinethiones were synthesized using previous reported methods and determined by 1H-NMR, 13C-NMR and ESI-MS analysis.

Minimum inhibitory concentrations (MICs). The MICs against Mycobacterium tuberculosis H37Rv and Erdman were determined by the microplate Alamar blue assay. Compound stock solutions were prepared in Dimethyl sulfoxide (DMSO). The final test concentrations ranged from 32 to 0.0078 μg/mL. M. tuberculosis was grown to late log phase in Middlebrook 7H9 medium supplemented with 0.05% Tween 80, 0.2% (vol/vol) glycerol, and 10% (vol/vol) oleic acid-albumin-dextrose-catalase. Cultures were then centrifuged, washed, and resuspended in phosphate-buffered saline. Suspensions were then passed through an 8-um-pore-size filter to remove clumps, and aliquots were frozen at −80 °C. The number of CFU was determined by plating on 7H11 agar plates.

Two-fold dilutions of compounds were prepared in Middlebrook 7H12 medium in a volume of 100 μL in 96-well microplates. M.tb (100 μL inoculum of 106 cfu/mL) was added, the plates were incubated at 37 °C. On the
7th day, add 20μL 0.01% Alamar Blue and 12.5μL of 20% Tween 80 to each well. After 24 hours the fluorescence of each well is measured at Excitation 530 nm; Emission 590 nm.

The MICs against *Mycobacterium tuberculosis* clinical isolates, *Mycobacterium avium* were determined by a microdilution plate assay. Final drug concentration ranges were as follows: for *Mycobacterium avium*, 0.00125 to 64μg/mL, for MDR-TB and XDR-TB strains, 0.0156 to 64μg/mL. Isoniazid (INH) or RMP was used as positive control in each experiment, control wells were prepared with bacterial suspension only.

The MICs were defined as the lowest concentration effecting a reduction in fluorescence of ≥90% relative to the controls. Reported MICs are an average of two or three individual measurements.

**Checkerboard synergy assay.** Briefly, in a 96-well microtiter plate, two-fold serial dilutions of compound A were added vertically. Compound B (benzothiazinethiones or benzothiazineones) was diluted horizontally, and the row and column in this plate contained individual drugs can be used calculated individual MIC. To each well of plate, a log-phase culture of bacteria was added. The plates incubated for 14 days at 37 °C prior to reading MICs. Fractional inhibitory concentrations (FIC) were calculated using the following formula: MIC in combination/MIC alone. The fractional inhibitory concentration index FICI was calculated as the sum of FIC of compound A + FIC of compound B. As outlined in previous publications about the assay, FICI scores were explained as follows: synergy (FICI ≤0.5), additivity (0.5–4.0), or antagonism (FICI >4.0).

**Macrophage assay.** As described previously, J774.1 cells were grown in 75-cm² cell culture flasks in 10% FBS in Dulbecco’s modified Eagle’s medium (DMEM) until confluent. The cells were detached using a cell scraper, and then centrifuged at 200 g for 5 min at room temperature. The cells were incubated at 37 °C under 5% CO₂ for 16 h after distributing into 24-well plates containing coverslips. *M. tuberculosis* Erdman (ATCC 35801) were diluted to a final concentration of 1 × 10⁶ to 3 × 10⁶ CFU/mL with DMEM after thawing and sonication from frozen cultures. And 500 ul of the dilution was dispensed to each well of a new 24-well plate. Followed by, J774.1 cells on coverslips were infected by incubation with *M. tuberculosis* Erdman at 37 °C for 2 h. Coverslips were then washed with HBSS and transferred to new 24-well plates. The Cultures were treated in triplicate with compounds at 0.02μM containing DMEM and incubated at 37 °C for 3 weeks under 5% CO₂ for 16 h. At D 0 (untreated controls) and after 7 days of incubation, macrophage cultures were lysed by addition of 200μL of 0.25% sodium dodecyl sulfate. The plates were incubated at 37 °C for 10 min, and 200μL of DMEM was added. The lystate was sampled using a microtube and sonicated for 15 s. Then 1:1, 1:10, 1:100, and 1:1,000 dilutions were plated on 7H11 agar plates and CFU counts determined after 2 to 3 weeks of incubation at 37 °C.

**Cytotoxicity.** The compounds were examined for toxicity (IC₅₀) using MTT assay. Briefly, cells (3 ~ 5 × 10⁵ cells/well) were seeded in a 96-well plate. After 24 h incubation, the cells were treated with various concentrations of drugs for 24, 48, 72 h, respectively. Columns one and two in the assay plates contained-media and DMSO respectively. 10% DMSO was added vertically. Compound B (benzothiazinethiones or benzothiazineones) was diluted horizontally, and the row and column in this plate contained individual drugs can be used calculated individual MIC. To each well of plate, a log-phase culture of bacteria was added by incubation with 0.02μM containing DMEM and incubated at 37 °C for 3 weeks under 5% CO₂ for 16 h. At D 0 (untreated controls) and after 3 days of incubation, macrophage cultures were lysed by addition of 200μL of 0.25% sodium dodecyl sulfate. The plates were incubated at 37 °C for 10 min, and 200μL of DMEM was added. The lystate was sampled using a microtube and sonicated for 15 s. Then 1:1, 1:10, 1:100, and 1:1,000 dilutions were plated on 7H11 agar plates and CFU counts determined after 2 to 3 weeks of incubation at 37 °C.

**In vivo acute M. tb Erdman infection assay.** The studies were conducted by University of Illinois at Chicago and approved by the Institutional Animal Care and Treatment Committee and were carried out in accordance with the approved guidelines. Eight-week-old female BALB/c mice were infected with a suspension of *M. tuberculosis* Erdman/mL using a Glas-Col inhalation system. Following infection, the mice were randomized divided into 6 groups and each group was composed of 5 to 6 mice. 4 mice were sacrificed to determine the CFU counts in the lungs 3 days after infection. Therapy was given daily from day 10 until day 36 postinfection. BTZ043 and SKLB-TB1001 were suspended in 0.5% carboxymethyl cellulose (CMC), and RIF were suspended in water in the study. All the drugs were administered by oral gavage in a maximum volume of 200μL (RMP, 15 mg/kg; BTZ043 and SKLB-TB1001 150 mg/kg, respectively). The mice were sacrificed the day after the last day of treatment. Lungs were aseptically removed and were ground in a tissue homogenizer. The number of viable organisms was determined by titration on 7H11 agar plates in duplicate. The plates were incubated at 37 °C for 3 weeks before CFU were enumerated and CFU counts were log transformed before analysis.

**Pharmacokinetic study.** All animal experiments have been approved by the Institutional Animal Care and Treatment Committee of Sichuan University in China and were carried out in accordance with the approved guidelines. SPF female SD rats weighing 180–220 g were used in the pharmacokinetic study. The rats were fasted overnight before dosing. Every treatment group contain 3 rats. Rats were dosed with SKLB-TB1001 or BTZ034 suspension at 5 mg/kg (i.v. and p.o.). Compounds were dissolved in 5% DMSO/10% Solutol HS15 in saline for intravenous injection and suspended in 0.5% CMC for oral administration. Blood was collected from the jugular vein of each animal at the following times after administration of drugs: 0.083, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after a single i.v. dosing; and 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after a single oral dosing. All blood samples were centrifuged at 3000 rpm for 10 min to obtain serum which was then stored at −20 °C. 150 μL of the serum was added to 500μL of acetonitrile and the mixture was centrifuged at 13000 rpm for 10 min to remove protein. The supernatant was dried and dissolve in 100μL of acetonitrile, the solution was centrifuged at 13000 rpm for 10 min. The supernatant was moved to a sample bottle for HPLC analysis. Total area under the concentration time curve (AUC), the elimination half-time (t₁/₂), the peak concentration (Cₘₐₓ) and the time to reach peak concentration (Tₘₐₓ) of samples were determined directly from the experimental data using WinNonlin V6.2.1.

**In vivo acute toxicity study.** All animal experiments have been approved by the Institutional Animal Care and Treatment Committee of Sichuan University in China and were carried out in accordance with the approved
guidelines. 20 BALB/c mice in both sexes were administered with SKLB-TB1001 CMC suspension at 1 g/kg by intraperitoneal injection, control mice remained untreated. Animals were continuously observed for 24 hours after administration. In each group, numbers of deaths and general behavior were recorded within 2 weeks. LD₅₀ values were calculated. 2 weeks later, animals were sacrificed, blood samples were collected from the eye vein for biochemical and hematological tests. The organs and tissues of animals were removed and fixed in 10% formalin and embedded in paraffin for histological evaluation.

**Statistical analysis.** Statistical analysis was analyzed by 2-tailed Student’s t test. In all statistical analysis, P values < 0.05 were considered to be statistically significant.

**References**
1. WHO. Global tuberculosis report. (World Health Organization, 2015).
2. Poce, G. et al. Sar analysis of new anti-tb drugs currently in pre-clinical and clinical development. *Eur J Med Chem* **86**, 335–351 (2014).
3. Benoit, L. et al. Tuberculosis drug discovery in the post-post-genomic era. *EMBO Mol Med* **6**, 158–168 (2014).
4. Zhao, Y. et al. National survey of drug-resistant tuberculosis in China. *N Engl J Med* **366**, 2161–2170 (2012).
5. Chaisson, R. E. & Nuerenberger, E. L. Confronting multidrug-resistant tuberculosis. *New Engl J Med* **366**, 2223–2224 (2012).
6. Koen, A. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. *Science* **307**, 223–227 (2005).
7. Makoto, M. et al. OPC-67683, a nitro-dihydro-imidazoazoxazole derivative with promising action against tuberculosis in vitro and in mice. *PloS Med* **3**, e466 (2006).
8. Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature* **405**, 962–966 (2000).
9. Lienhardt, C. et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. *J Infect Dis* **205**, S241–249 (2013).
10. Bifani, P. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. *Nat Med* **19**, 1157–1160 (2013).
11. Cohen, J. Infectious disease. Approval of novel TB drug celebrated—with restraint. *N Engl J Med* **373**, 1041–1045 (2014).
12. Ryan, N. J. & Jin, H. L. Delamanid: first global approval. *Drugs* **74**, 1041–1045 (2014).
13. Yong-Soo, K., Byeong-Ho, J. & Won-Jung, K. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. *Expert Opin Pharmacother* **16**, 1–9 (2015).
14. Espósito, S., Bianchini, S. & Blasi, F. Bedaquiline and delamanid in tuberculosis. *Expert Opin Pharmacother* **16**, 2319–2330 (2015).
15. Barry, C. E. Timing is everything for compassionate use of delamanid. *J Infect Dis* **205**, S230–S237 (2014).
16. Bloemberg, G. V. et al. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. *N Engl J Med* **373**, 1986–1998 (2015).
17. Manina, G. et al. Decaprenylphosphoryl-beta-d-ribose 2’-epimerase from mycobacterium tuberculosis is a magic drug target. *Curr Med Chem* **17**, 1099–1108 (2010).
18. Giuvanna, R. et al. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. *Appl Microbiol Biotechnol* **97**, 8841–8848 (2013).
19. Brecik, M. et al. DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization. *ACS Chem Biol* **10**, 1631–1636 (2015).
20. Makarov, V. & Benzoizahizinones kill Mycobacterium tuberculosis by blocking arabinan synthase. *Science* **324**, 801–804 (2009).
21. Paul, K. et al. Decaprenylphosphoryl-3’-D-ribose 2’-epimerase, the target of benzoizahizinones and dintrobenzamides, is an essential enzyme in Mycobacterium smithii. *PloS One* **6**, e16869 (2011).
22. Stanley, S. A. et al. Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening. *ACS Chem Biol* **7**, 1377–1384 (2012).
23. Ding, S. Q. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. *Proc Natl Acad Sci USA* **110**, 15848–15849 (2013).
24. Maruti, N. et al. 4-aminoquinolinone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antitubercular activity. *J Med Chem* **57**, 5419–5434 (2014).
25. Manoranjan, P. et al. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. *J Med Chem* **57**, 4761–4771 (2014).
26. Shirude, P. S. et al. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. *J Med Chem* **56**, 9701–9708 (2013).
27. Makarov, V. et al. Towards a new combination therapy for tuberculosis with next generation benzoizahizinones. *EMBO Mol Med* **6**, 372–383 (2014).
28. Tomislav, K. et al. Identification of antibacterial benzoizahizinone compounds by ligand-based design. *J Med Chem* **55**, 7940–7944 (2012).
29. Batt, S. M. et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzoizahizinone inhibitors. *Proc Natl Acad Sci USA* **109**, 11354–11359 (2012).
30. João, N. et al. Structural basis for benzoizahizinone-mediated killing of Mycobacterium tuberculosis. *Sci Transl Med* **4**, 1596–1609 (2012).
31. Gao, C. et al. Synthesis and structure-activity relationships evaluation of benzoizahizinone derivatives as potential anti-tubercular agents. *Biores Biomed Chem Lett* **23**, 4919–4922 (2013).
32. Peng, C. T. et al. Synthesis and antibacterial evaluation of 4-carbonyl piperazine substituted 1,3-benzoizahizin-4-one derivatives. *Biores Biomed Chem Lett* **25**, 1375–1376 (2015).
33. Kigondu, E. M. et al. Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in tuberculosis drug discovery. *Biores Biomed Chem Lett* **22**, 4453–4461 (2014).
34. Salama, K. & Farmer, P. E. Tuberculosis, drug resistance, and the history of modern medicine. *N Engl J Med* **367**, 931–936 (2012).
35. Benoit, L., Hartikko, R. C. & Cole, S. T. In vitro combination studies of benzoizahizinone lead compound BTZ043 against Mycobacterium tuberculosis. *Antimicrob Agents Chemother* **56**, 5790–5793 (2012).
36. Carlens, L. Action of oxygen on thiobenzenophene in the dark. *J Org Chem* **41**, 2971–2973 (1976).
37. Ramnath, N. et al. Photo chemical oxidation of thio ketones: steric and electronic aspects. *J Org Chem* **48**, 214–222 (1983).
38. Malwal, S. R. et al. Design, Synthesis, and Evaluation of Thiol-Activated Sources of Sulfur Dioxide (SO2) as Antimycobacterial Agents. *J Med Chem* **55**, 353–357 (2012).
39. Shi, X. et al. 8-Hydroxy-2’-deoxyguanosine Formation and DNA Damage Induced by Sulfur Trioxide Anion Radicals. *Biochem Biophys Res Commun* **205**, 141–147 (1994).
40. Armentia-Alvarez, A. et al. Residual levels of free and total sulphite in fresh and cooked burgers. *Food Addit Contam* **10**, 157–65 (1993).
41. Campbell, E. A. et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cell* **104**, 901–912 (2001).
42. Sirgel, F. A. et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. *J Antimicrob Chemother* **67**, 1088–1093 (2012).
43. Jesús, F. et al. Linezolid for the treatment of multidrug-resistant tuberculosis. *J Antimicrob Chemother* **56**, 180–185 (2005).
44. Franzblau, S. G. et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. *Tuberculosis (Edinb)* **92**, 453–488 (2012).
45. Lun, S. et al. Indoleamides are active against drug-resistant Mycobacterium tuberculosis. *J Antimicrob Chemother* **67**, 1088–1093 (2012).
46. Blaser, A. et al. Structure-activity relationships for anide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-[(trifluoromethoxy)benzyl]oxy-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). *J Med Chem* **55**, 312–26 (2012).
47. Collins, L. et al. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. *Antimicrob Agents Chemother* **41**, 1004–1009 (1997).
48. Wallace, R. J. Jr. et al. Susceptibility Testing of Slowly Growing Mycobacteria by a Microdilution MIC Method with 7H9 Broth. *J Clin Microbiol* **24**, 976–981 (2005).
49. Falciani, E. et al. *In vitro* and *in vivo* activities of macrolide derivatives against mycobacterium tuberculosis. *Antimicrob Agents Chemother* **49**, 1447–1454 (2005).
50. Zhu, Y. et al. Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. *Sci Rep.* **6**, 20253 (2016).

**Acknowledgements**

The authors thank Baojie Wan for assistance with Mtb infection mouse model and Yuehong Wang for assistance with *in vitro* assays. Our special thanks also belong to Shanghai Pulmonary Hospital for their efforts in the screening on drug-resistant clinical isolates and to WuXi AppTec Co. Ltd. for the ADME/T studies *in vitro*. Grant support: This work was supported by The National Science and Technology Major Project of China (2012ZX09103101-021).

**Author Contributions**

C.G., C.P., T.-h.Y. and L.Y. conceived and designed the experiments. C.G., C.P., Y.S., X.Y. and Y.Z. performed most of the biological and pharmacokinetic experiments. C.G., K.R., L.X., L.Z. and N.W. performed the chemistry experiments. C.G., C.P., K.L., L.Y. and Y.W. analyzed the data. C.G., C.P., L.Z., W.Z. and Y.Z. wrote the main manuscript text. All the authors critically reviewed the manuscript.

**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Gao, C. et al. Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis. *Sci. Rep.* **6**, 29717; doi: 10.1038/srep29717 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/